Microarray technology has broad applications in cancer research such as identification of cancer markers and gene expression profiling for diagnosis, treatment, and prognosis. Maintenance of a Core DNA Microarray Facility in a comprehensive cancer research center is critical for the success of a growing number of investigators with peer-reviewed funding. The Microarray Facility was established in 1999 using institutional and developmental funds from the CCSG. The Facility provides both printed cDNA and oligo arrays, for investigators to perform gene expression analysis, and full microarray services from RNA sample labeling to array scanning, for those investigators who do not have the capacity to perform microarray experiments in their own laboratories. The Facility also helps investigators to design and print custom microarrays to meet their specific research goals. The Facility is used by 20 investigators, all with peer-reviewed funding, from 9 research Programs in all three Divisions of Fox Chase Cancer Center (FCCC). The microarray usage has increased more than 200% from the year 2002 to 2003 and reached 1,300 microarrays per year. With an increasing number of research grants involving microarray analysis awarded recently, and the establishment of a Laser Capture Microdissection Facility at the Center, combined with RNA amplification procedure which enables small clinical cancer samples to be applied to microarray analysis, we anticipate a 100%-200% increase over the next five years. The microarray products of the Facility include human 40k cDNA and 30k oligo arrays, mouse 15k cDNA and 32k oligo arrays, and 6k yeast oligo arrays. A rat oligo library will be acquired to meet the needs of those investigators using rat models to study breast and ovarian oncogenesis. The Facility has also designed and produced customer design specific arrays, such as DNA repair process-related gene arrays. Standard microarray procedures and optimized labeling and hybridization kits, as well as a Microarray Training Program, have been made available to microarray users. A comprehensive microarray quality control procedure has been implemented to ensure the quality of microarray products and services. The Facility coordinates with the Bioinformatics Facility for microarray data analysis and management.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-44
Application #
7310517
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
44
Fiscal Year
2006
Total Cost
$121,761
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Shaikh, Talha; Wang, Lora S; Egleston, Brian et al. (2018) Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Am J Clin Oncol 41:59-64
Campbell, Kerry S; Cohen, Adam D; Pazina, Tatiana (2018) Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. Front Immunol 9:2551
Blackman, Elizabeth; Ashing, Kimlin; Gibbs, Denise et al. (2018) The Cancer Prevention Project of Philadelphia: preliminary findings examining diversity among the African diaspora. Ethn Health :1-17
Fatkhullina, Aliia R; Peshkova, Iuliia O; Dzutsev, Amiran et al. (2018) An Interleukin-23-Interleukin-22 Axis Regulates Intestinal Microbial Homeostasis to Protect from Diet-Induced Atherosclerosis. Immunity 49:943-957.e9
Gupta, Sapna; Kelow, Simon; Wang, Liqun et al. (2018) Mouse modeling and structural analysis of the p.G307S mutation in human cystathionine ?-synthase (CBS) reveal effects on CBS activity but not stability. J Biol Chem 293:13921-13931
Sementino, Eleonora; Menges, Craig W; Kadariya, Yuwaraj et al. (2018) Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. J Cell Physiol 233:8952-8961
Araiza-Olivera, Daniela; Chernoff, Jonathan (2018) Hras helps hippo heterodimerize to evade tumor suppression. Small GTPases 9:327-331
Peng, Hongzhuang; Prokop, Jeremy; Karar, Jayashree et al. (2018) Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains. Cancer Res 78:1200-1213
Reese, Jennifer Barsky; Smith, Katherine Clegg; Handorf, Elizabeth et al. (2018) A randomized pilot trial of a couple-based intervention addressing sexual concerns for breast cancer survivors. J Psychosoc Oncol :1-22
Shaikh, Talha; Handorf, Elizabeth A; Meyer, Joshua E et al. (2018) Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults. JAMA Oncol 4:e173580

Showing the most recent 10 out of 1280 publications